Promoting higher-valent pediatric combination vaccines in China: challenges and recommendations for action

Table 3 China’s current NIP schedule and coverage (as of 2021)

Target antigen	Vaccine	Age															Coverage of antigen (%)
Target antigen	Vaccine	At birth	1 m	2 m	3 m	4 m	5 m	6 m	8 m	9 m	18 m	2 y	3 y	4 y	5 y	6 y	Coverage of antigen (%)
HepB virus	HepB	1	2					3									99.2
Mycobacterium tuberculosis	BCG	1															99.7
Poliomyelitis virus	IPV			1	2												99.2
Poliomyelitis virus	bOPV					3								4			99.2
Diphtheria, tetanus, pertussis	DTaP				1	2	3				4						98.8
Diphtheria, tetanus, pertussis	DT															5	98.8
Measles, mumps, rubella	MMR								1		2						99.1
Japanese encephalitis virus	JE-L								1			2					99.1
Japanese encephalitis virus	JE-I								1 and 2			3				4	99.1
Neisseria meningitidis	MPSV-A																99.6
Neisseria meningitidis	MPSV-AC												3			4	99.2
HepA virus	HepA-L										1						99.2
HepA virus	HepA-I										1	2					–

m means months, y means years, – means not applicable
HepB Hepatitis B; BCG Bacillus Calmette-Guérin; IPV Inactivated poliovirus vaccine; bOPV Bivalent oral polio vaccine; DTaP Diphtheria, tetanus, and acellular pertussis; DT Diphtheria, tetanus; MMR Measles, mumps, and rubella; JE-L Live-attenuated Japanese encephalitis vaccine; JE-I Inactivated Japanese encephalitis vaccine; MPSV-A Group A meningococcal polysaccharide vaccine; MPSV-AC Group A and Group C meningococcal polysaccharide vaccine; HepA-L Live-attenuated hepatitis A; HepA-I Inactivated hepatitis A

ISSN: 2049-9957